Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07021157 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety, Tolerability and PK of SK-08

Study acronym: SK-08
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 24, 2025 (before its estimated August 7, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revisedv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The trial is conducted in a single-center, randomized, double-blind, placebo-controlled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) ,and pharmacodynamics (PD) characteristics of SK-08 in healthy participants.
Trial Details
NCT Number NCT07021157
Lead Sponsor Consun Pharmaceutical Group
Conditions
(from sponsor)		 Chronic Kidney Disease(CKD)
Related terms Renal Insufficiency, Chronic
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov